Nuclear Factor-κB-Independent Anti-Inflammatory Action of Salicylate in Human Endothelial Cells: Induction of Heme Oxygenase-1 by the c-Jun N-Terminal Kinase/Activator Protein-1 Pathway
Authors:
- Robert FürstRFRobert Fürst
- Signe B. BlumenthalSBSigne B. Blumenthal
- Alexandra K. KiemerAKAlexandra K. Kiemer
- Stefan ZahlerSZStefan Zahler
- Angelika M. VollmarAVAngelika M. Vollmar
- 1 July 2006
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (1) , 389-394
Abstract
In contrast to aspirin, salicylate, its active metabolite, possesses profound anti-inflammatory properties without blocking cyclooxygenase. Inhibition of the transcription factor nuclear factor-kappaB (NF-kappaB) has been discussed to play a role in the anti-inflammatory profile of salicylate. However, NF-kappaB-independent effects of salicylate have been assumed but have up to now been poorly investigated. Therefore, the aim of the present study was to investigate NF-kappaB-independent anti-inflammatory mechanisms of salicylate in human umbilical vein endothelial cells using interleukin-4 (IL-4) as NF-kappaB-independent proinflammatory stimulus and P-selectin as inflammatory read-out parameter. Using quantitative real-time reverse transcription-polymerase chain reaction, we found that salicylate decreases IL-4-induced P-selectin expression. As judged by Western blot analysis, salicylate increased endothelial heme oxygenase-1 (HO-1) protein levels. Using both the HO-1 inhibitor tin(II) protoporphyrin IX and HO-1 antisense oligonucleotides, we causally linked the induction of HO-1 to the decrease of P-selectin. Moreover, we were interested in the signaling mechanisms leading to the up-regulation of HO-1 by salicylate. c-Jun NH2-terminal kinase (JNK) was found to be activated by salicylate, and we could causally link this activation to the induction of HO-1 by using the JNK inhibitor 1,9-pyrazoloanthrone. By applying activator protein-1 (AP-1) decoys, it was shown that the transcription factor AP-1 is crucially involved in the up-regulation of HO-1 downstream of JNK. In summary, our study introduces HO-1 as novel NF-kappaB-independent anti-inflammatory target of salicylate in human endothelial cells. Moreover, we elucidated the JNK/AP-1 pathway as crucial for the induction of HO-1 by salicylate.Keywords
This publication has 40 references indexed in Scilit:
- Oxidative Stress Is Responsible for Mitochondrial Permeability Transition Induction by Salicylate in Liver MitochondriaJournal of Biological Chemistry, 2005
- Atrial Natriuretic Peptide Induces Mitogen-Activated Protein Kinase Phosphatase-1 in Human Endothelial Cells via Rac1 and NAD(P)H Oxidase/Nox2-ActivationCirculation Research, 2005
- A New Pharmacological Effect of Salicylates: Inhibition of NFAT-Dependent TranscriptionThe Journal of Immunology, 2004
- Anti-Inflammatory Actions of the Heme Oxygenase-1 PathwayCurrent Pharmaceutical Design, 2003
- SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinaseProceedings of the National Academy of Sciences, 2001
- Potential Dengue Virus-Triggered Apoptotic Pathway in Human Neuroblastoma Cells: Arachidonic Acid, Superoxide Anion, and NF-κB Are Sequentially InvolvedJournal of Virology, 2000
- Role of redox potential and reactive oxygen species in stress signalingOncogene, 1999
- Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκBProceedings of the National Academy of Sciences, 1999
- Interleukin 4 is localized to and released by human mast cells.Journal of Experimental Medicine, 1992
- Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation.Proceedings of the National Academy of Sciences, 1981